OPK-88006 vs pemvidutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
MASH / NASH
Shared mechanism: GLP-1/glucagon receptor (dual) · full MASH / NASH pipeline
OPK-88006
Developed by OPKO Health
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT07512427 (registry estimate)
No aligned efficacy figure on record for this race.
pemvidutide
Developed by Altimmune
NCT05989711 · Phase 2 · completed
IMPACT was a randomized, quadruple-blind, placebo-controlled Phase 2b in 212 patients with MASH with two biopsy co-primary endpoints. MASH resolution was met at both doses; fibrosis improvement did not reach statistical significance, so the primary comparison was only partly met and the grade is moderate.
Next expected readout: December 2028 · NCT07795164 (registry estimate)
Reported efficacy
Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosis (24 weeks); Proportion of subjects achieving at least 1 stage improvement in liver fibrosis without worsening of NASH (defined as no change in the NAS, ie, the sum score for ballooning, inflammation, and steatosis) (24 weeks); Incidence of Treatment Emergent Adverse Events (52 weeks): Co-primary endpoints at week 24 (ITT): MASH resolution without fibrosis worsening 59.1% (1.2 mg) and 52.1% (1.8 mg) vs 19.1% placebo (p<0.0001); fibrosis improvement without MASH worsening 31.8% and 34.5% vs 25.9%, not statistically significant (HCPLive, 2025-06-26). (mixed)
Result source: NCT05989711
Results for MASH / NASH
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | OPK-88006 | pemvidutide |
|---|---|---|
| MASH resolution without fibrosis worsening | —Not reported | 52.1% vs 19.1%a+33 vs placeboNCT059897111 other result
|
| Fibrosis stage, change | —Not reported | —Trial running · NCT07795164 |
| Liver fat (MRI-PDFF), change | —Not reported | —Trial running · NCT07795164 |
| ALT, change | —Not reported | —Trial running · NCT07795164 |
MASH resolution without fibrosis worsening
- OPK-88006
- —Not reported
- pemvidutide
- 52.1% vs 19.1%a+33 vs placeboNCT05989711
1 other result
- 59.1% vs 19.1% NCT05989711
Fibrosis stage, change
- OPK-88006
- —Not reported
- pemvidutide
- —Trial running · NCT07795164
Liver fat (MRI-PDFF), change
- OPK-88006
- —Not reported
- pemvidutide
- —Trial running · NCT07795164
ALT, change
- OPK-88006
- —Not reported
- pemvidutide
- —Trial running · NCT07795164
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
OPK-88006: no structured comparison results are available for MASH / NASH.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
pemvidutide
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: OPK-88006's landscape · pemvidutide's landscape